Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Free Cash Flow (2016 - 2025)

Tandem Diabetes Care's Free Cash Flow history spans 13 years, with the latest figure at $6.9 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 9.52% year-over-year to $6.9 million; the TTM value through Dec 2025 reached -$13.4 million, down 368.72%, while the annual FY2025 figure was -$13.4 million, 368.72% down from the prior year.
  • Free Cash Flow reached $6.9 million in Q4 2025 per TNDM's latest filing, down from $16.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $34.4 million in Q3 2022 to a low of -$24.0 million in Q4 2022.
  • Average Free Cash Flow over 5 years is $4.2 million, with a median of $7.3 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: soared 533.03% in 2021, then crashed 340.33% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $19.5 million in 2021, then crashed by 222.57% to -$24.0 million in 2022, then skyrocketed by 147.76% to $11.4 million in 2023, then plummeted by 33.16% to $7.6 million in 2024, then decreased by 9.52% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Free Cash Flow are $6.9 million (Q4 2025), $16.6 million (Q3 2025), and -$15.7 million (Q2 2025).